Skip to main content

Intradialytic Hypotension

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Ear pillsPhase 2/31 trial
Active Trials
NCT02583802Unknown150Est. Dec 2015
Pharvaris
PharvarisNetherlands - Leiden
1 program
IcatibantPHASE_31 trial
Active Trials
NCT05834777Recruiting26Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharvarisIcatibant
Integrated BiosciencesEar pills

Clinical Trials (2)

Total enrollment: 176 patients across 2 trials

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

Start: Dec 2023Est. completion: Nov 202626 patients
Phase 3Recruiting

The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients

Start: Sep 2013Est. completion: Dec 2015150 patients
Phase 2/3Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 176 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.